The IBS Secondaries Private Equity Fund VI invests in two best-in-class secondary private equity funds. In addition, we invest directly in secondary deals through exclusive co-investments in collaboration with the private equity managers in the IBS network via the IBS Vantage Point Secondary Fund I.
The IBS fund is expected to:
The fund is currently open to new participants. Would you like to know more about the
IBS Secondaries Private Equity Fund VI? Please contact one of our specialists.
The underlying strategy is aimed at the ‘middle market’ segment: growth companies that are in the phase just before an IPO or a sale to a larger investor. This market segment is characterised by an interesting combination of lower valuations, lower debt levels and significant growth potential.
The focus is on profitable companies with a high-quality business model. These companies benefit from structural growth trends due to technological or demographic developments. This includes industries such as technology, healthcare, automation, B2B services, e-commerce, and fintech.
Secondary managers have historically performed well in turbulent markets. This stems from two trends:
Co-investments offer the opportunity to participate directly in specific companies at the invitation of private equity managers (read more about this in our blog). The allocation to the underlying IBS Vantage Point Secondary Fund allows us to select direct GP-led investments from the deal flow of both secondary private equity funds.
In addition, this fund allows us to enter into co-investments with other secondary managers within the IBS network. In this way, we make optimal use of our entire private equity network.
On average, co-investments generate more favourable returns than fund investments, partly because you do not pay any management and performance fees on the co-investments.
The Rothschild Five Arrows Secondaries Opportunities Fund VII invests in GP-led secondaries. It enters into partnerships with a private equity managers, who want to continue to manage their best companies for a couple more years. FASO is the capital provider in this transaction and helps with new investments, capital reallocation and fund restructuring, among other things. The FASO VII fund focuses on high-quality companies that benefit from megatrends and are active in IT, B2B services and healthcare.
The AlpInvest Secondaries Fund IX is a secondary private equity fund. The fund’s strategy is twofold. First, it buys fund participations from third parties. The focus is on buying participations from high-quality primary private equity managers at a discount on the underlying asset (‘LP-led Secondaries’). In addition, it sets up continuation structures in collaboration with private equity managers (‘GP-led Secondaries’). In doing so, it provides capital so that the private equity managers can continue to develop their best companies for a couple more years. The fund focuses on high-quality companies. These are companies with solid growth, stable profits and a strong competitive position in a wide range of sectors.
The prospectuses of the closed-end investment funds managed for IBS Fund Management B.V. and those of the underlying master investment funds are available at the request of the participants (in the secure part of the site and via [email protected]).
